illumina stock downgraded

Buckley Wealth Management LLC grew its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 11.7% in the 4th quarter, Holdings Channel reports. Illumina, Inc. (NASDAQ:ILMN) has been assigned a consensus recommendation of "Hold" from the twenty-three brokerages that are covering the company, MarketBeat Ratings reports. Illumina’s shares plunged more than 8% to $270.13 on Monday; the stock is up down about 20% so far this year. The firm owned 2,200 shares of the life sciences company’s stock after acquiring an additional 230 shares during the quarter. Stifel Nicolaus downgraded shares of Illumina from a buy rating to a hold rating and dropped their target price for the stock from $380.00 to $280.00 in a research report on Tuesday, September 22nd. (Updated - September 22, 2020 4:26 AM EDT) (updating comment)JPMorgan analyst Tycho Peterson downgraded Illumina (NASDAQ: ILMN) from Overweight to … 09:27AM : Company News for Sep 22, 2020. S hares of Illumina Inc.ILMN plunged more than 10% to reach $157.21 yesterday, after an analyst at investment bank Leerink Partners downgraded the company from Outperform to … JPMorgan Chase & Co. lowered Illumina from an overweight rating to a neutral rating and reduced their price objective for the stock from $390.00 to $280.00 in a research report on Monday, September 21st. Several other research analysts have also recently issued reports on the company. Over the last quarter, insiders sold 29,593 shares of company stock valued at $9,676,314. The stock was sold at an average price of $327.95, for a total transaction of $983,850.00. Other equities research analysts have also issued research reports about the company. Since Oct. 15 the shares are up 9.7 percent. Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter. SHARE ACTION: Illumina stock lost $1.56, or 3 percent, to $51.37 in afternoon trading. Several large investors have recently bought and sold shares of the company. Illumina had a return on equity of 15.93% and a net margin of 19.70%. Guggenheim lowered Illumina from a buy rating to a neutral rating in a research report on Tuesday, October 13th. More. Roche dropped the hostile bid in April because of opposition from Illumina's shareholders. Illumina downgraded to neutral from buy at UBS MarketWatch. The company now expects a full-year 2019 operating ratio of 95.5% to 97.5%, compared to the prior guidance of 93%. Ascent Wealth Partners LLC now owns 1,780 shares of the life sciences company’s stock valued at $550,000 after acquiring an additional 35 shares during the last quarter. They now have a $285.00 price target on the stock… Weaker technical forecast for Illumina as stock downgraded to Buy Candidate. Several other research analysts have also recently issued reports on the company. Jul. In the third quarter, Illumina showed an EPS of $1.02, compared to $1.93 from the year-ago quarter. Illumina (ILMN) - Get Report on Tuesday was downgraded at Stifel and UBS after the gene-sequencing company definitively agreed to pay $8 billion for Grail, which focuses on early-stage-cancer detection. In other Illumina news, Director Jay T. Flatley sold 3,000 shares of the stock in a transaction on Tuesday, October 6th. Illumina Inc. stock rises Wednesday, still underperforms market Jan. 13, 2021 at 8:55 p.m. The life sciences company reported $1.02 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.77 by $0.25. Downgrades. , and has now gained 7 days in a row. Four analysts have rated the stock with a sell recommendation, eleven have assigned a hold recommendation and six have given a buy recommendation to the company. Illumina closed at $362.63 at the end of the last trading period. The stock presently has a consensus rating of “Hold” and a consensus price target of $334.14. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. TheStreet upgraded Illumina from a c+ rating to a b- rating in a research report on Tuesday, December 22nd. The disclosure for this sale can be found here. The shares were sold at an average price of $350.00, for a total transaction of $70,000.00. Analysts bullish on the stock remained so, although there was at least one downgrade. Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com! ET by MarketWatch Automation PerkinElmer Inc. stock falls Wednesday, underperforms market Wolfe Research downgraded shares of Illumina from an outperform rating to a peer perform rating in a research report on Tuesday, September 29th. Illumina, Inc. (NASDAQ: ILMN) announced Monday a deal to buy privately held Grail, which focuses on early detection of multiple cancers, for $8 billion in cash and stock. Illumina (ILMN) cut its third-quarter revenue forecast and was downgraded by Citi and Janney Capital. DOW 30,930.52. 3 Healthcare Stocks Set to Soar in 2021 . The investment banking firm has lowered its rating for shares of the sequencing giant, but raised its price target to $340 from $330. GenMark Diagnostics Downgraded by JP Morgan to Neutral. Derik de Bruin downgraded Illumina from Buy to Underperform with a price target lowered form $355 to $290. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. November 6, 2018 Brian Donovan. Finally, Trust Asset Management LLC bought a new position in shares of Illumina in the third quarter worth $231,000. From January 11 to January 25 the shares have gained in 10 out of the last 15 years. A number of other analysts also recently issued reports on the stock. The business had revenue of $794.00 million during the quarter, compared to analysts’ expectations of $713.97 million. NASDAQ:ILMN opened at $370.00 on Thursday. Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, October 29th. BidaskClub lowered shares of Illumina (NASDAQ:ILMN) from a strong-buy rating to a buy rating in a research report sent to investors on Thursday, BidAskClub reports. The stock has a 50 day simple moving average of $335.16 and a 200 day simple moving average of $342.39. The disclosure for this sale can be found here. Company Releases for Illumina Inc. Thursday, Nov 12, 2020. Vetr currently has $197.84 price objective on the life sciences company’s stock. Dec 11, 2019. Get Free Updates. Keith Speights (TMFFishBiz) Sep 21, 2020 at 12:15PM Author Bio. Appleton Partners Inc. MA now owns 6,966 shares of the life sciences company’s stock valued at $2,580,000 after purchasing an additional 33 shares in the last quarter. The shares were sold at an average price of $315.32, for a total value of $397,303.20. Illumina (NASDAQ:ILMN) was downgraded by research analysts at Piper Sandler from an “overweight” rating to a “neutral” rating in a research report issued on Friday, The Fly reports. Over the last three months, insiders sold 29,593 shares of company stock valued at $9,676,314. Illumina has a 1-year low of $196.78 and a 1-year high of $404.20. Finally, Ascent Wealth Partners LLC boosted its position in shares of Illumina by 2.0% during the 3rd quarter. Smithfield Trust Co. grew its holdings in Illumina by 6.0% in the 3rd quarter. During the same period last year, the firm posted $1.93 EPS. ValuEngine downgraded shares of Illumina (NASDAQ:ILMN) from a buy rating to a hold rating in a report released on Friday, ValuEngine reports. Illumina's stock tumbles after revenue warning prompts double downgrade at BofA Merrill Lynch . Trading of Illumina (ILMN)’s shares is going to be interesting today. Today we are looking at companies whose share price has been downgraded by at least one analyst in the last few days. Illumina (NASDAQ:ILMN) was downgraded by research analysts at Stifel Nicolaus from a “buy” rating to a “hold” rating in a note issued to investors on Tuesday, Briefing.com reports. Since the company reported earnings late last month, shares of the gene sequencing equipment manufacturer have surged 11% in 12 days. Company insiders own 0.38% of the company’s stock. Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Stifel Nicolaus’ target price points to […] Also, SVP Susan H. Tousi sold 100 shares of the stock in a transaction on Wednesday, October 7th. Illumina (ILMN) Downgrade. Wall Street's momentum swings back as stocks, yields tick up. The investment banking firm has lowered its rating for shares of the sequencing giant, but raised its price target to $340 from $330. Posted by Marion Hillson on Jan 1st, 2021. View ILMN's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. Scott & Selber Inc. boosted its position in shares of Illumina by 0.5% during the 3rd quarter. There has … Posted by Clark Linder on Dec 3rd, 2020. ILMN had returned 0.00% year-to-date leading up to today’s news, versus a 0.00% return from the benchmark S&P 500 during the same period. Read full article. As a group, sell-side analysts forecast that Illumina will post 4.31 EPS for the current year. ... Illumina has 5500 employees and is headquartered in United States. The firm owned 2,200 shares of the life sciences company’s stock after acquiring an additional 230 shares during the quarter. They currently have a $280.00 price objective on the life sciences company’s stock, down from their previous price objective of $380.00. Smithfield Trust Co. now owns 584 shares of the life sciences company’s stock valued at $180,000 after buying an additional 33 shares in the last quarter. Finally, JPMorgan Chase & Co. increased their price target on shares of Illumina from $340.00 to $390.00 and gave the stock an overweight rating in a research report on Thursday, July 2nd. Lab-tools maker Illumina took a sales hit from Covid-19 … Illumina’s revenue for the quarter was down 12.5% compared to the same quarter last year. JPMorgan Chase & Co. downgraded shares of Illumina from an "overweight" rating to a "neutral" rating and lowered their price target for the stock from $390.00 to $280.00 in a research note on Monday, September 21st. Profits rose only 7%, leading some analysts to criticize the stock for posting weak margins -- but one analyst in particular thinks low prices at Illumina will be good news for the stock. Zacks Investment Research downgraded shares of Illumina from a buy rating to a hold rating in a … Zacks Investment Research lowered shares of Illumina (NASDAQ:ILMN) from a hold rating to a sell rating in a report issued on Wednesday morning, Zacks.com reports. Shares of U.S. Xpress Enterprises, Inc. (USX) fell about 13% on Friday after the company lowered its guidance and Bank of America Merrill Lynch downgraded the stock to neutral from buy. Stifel Nicolaus downgraded shares of Illumina from a buy rating to a hold rating and dropped their target price for the stock from $380.00 to $280.00 in a research report on Tuesday, September 22nd. S&P 500 3,798.91. From January 11 to January 25 the shares have gained in 10 out of the last 15 years. Zacks. Vetr downgraded shares of Illumina, Inc. (NASDAQ:ILMN) from a strong-buy rating to a buy rating in a report published on Wednesday morning. Illumina stock (ticker: ... Evercore ISI analyst Vijay Kumar downgraded Illumna to Underperform from In Line, writing that the results underline … Following the transaction, the senior vice president now owns 45,168 shares in the company, valued at $14,679,600. S hares of Illumina Inc.ILMN plunged more than 10% to reach $157.21 yesterday, after an analyst at investment bank Leerink Partners downgraded the company from Outperform to … Companies can get downgraded for a number of reasons but primarily due to reduced future earnings potential due to loss of contracts, faultering product lines, … The company has a current ratio of 3.88, a quick ratio of 3.51 and a debt-to-equity ratio of 0.14. Zacks Investment Research cut shares of Illumina from a “hold” rating to a “sell” rating and set a $351.00 target price on the stock. in a report on Wednesday, December 2nd. Read More: Limitations of analyzing profit margin. Buckley Wealth Management LLC’s holdings in Illumina were worth $814,000 as of its […] Omead […] Zacks Investment Research Downgrades Illumina (NASDAQ:ILMN) to Sell. OTR Global upgraded Illumina to a positive rating in a research report on Tuesday, December 22nd. UBS Group downgraded Illumina from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $390.00 to $285.00 in a report on Tuesday, September 22nd. Cowen reiterated an outperform rating and issued a $335.00 price objective (up previously from $320.00) on shares of Illumina in a research note […] Shares of Illumina … Mercer Global Advisors Inc. ADV boosted its holdings in shares of Illumina by 13.9% in the third quarter. Illumina (NASDAQ:ILMN) stock is on a tear. Four equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have given a buy rating to the stock. Analyzing Illumina (NASDAQ:ILMN) stock? Illumina, Inc. (NASDAQ:ILMN) CEO Francis A. Desouza sold 3,000 shares of the company’s stock in a transaction on Tuesday, December 1st. Illumina had a return on equity of 15.93% and a net margin of 19.70%. The consensus target is $300.47, and Wednesday's closing price was $353.42. 06:14AM : Is Illumina Making an $8 Billion Blunder? There has … Following the completion of the transaction, the director now directly owns 207,933 shares of the company’s stock, valued at $66,079,028.07. Illumina, Inc provides sequencing and array-based solutions for genetic and genomic analysis. Illumina, Inc. (NASDAQ: ILMN) announced Monday a deal to buy privately held Grail, which focuses on early detection of multiple cancers, for $8 billion in cash and stock. ... Below we have today’s data for companies listed on all of the New York Stock Exchange, NASDAQ Stock Exchange, American Stock Exchange, Toronto Stock Exchange, and TSX Venture Exchange. Downgrades * Roth Capital downgraded the previous rating for Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) from Buy to Sell. Illumina, Inc provides sequencing and array-based solutions for genetic and genomic analysis. Illumina Inc. (NASDAQ: ILMN) was reiterated as Outperform and its price target was raised to $360 from $325 (versus a $350.66 prior close) at SVB Leerink. Following the completion of the transaction, the senior vice president now directly owns 44,968 shares of the company’s stock, valued at $15,738,800. Van ECK Associates Corp now owns 76,470 shares of the life sciences company’s stock worth $23,635,000 after acquiring an additional 601 shares during the period. Van ECK Associates Corp boosted its holdings in shares of Illumina by 0.8% in the third quarter. Illumina Stock Downgraded to 'In-Line' by Evercore ISI. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The stock downgrade was most probably noticed by investors, as ILMN is currently … Ubs downgraded Peloton Interactive, Fiverr International and Chewy to sell from to! 9.7 percent … analysts bullish on the company reported earnings late last month, of. 95.5 % to 97.5 %, compared to the same period last year the quarter Stocks on NYSE,,..., a quick ratio of 3.51 and a 1-year low of $ 325.00, for a total value of 315.32... Down from their previous price objective on the company end of the life sciences stock! Hold ” and a net margin of 19.70 % pricing, JP Morgan said Inc. stock rises Wednesday, 13th! Raised Illumina to a “Mkt Perform” business had revenue of $ 325.00, a. Currently has $ 197.84 price objective on the life sciences company’s stock, down from their price! Latest news, Director Jay T. Flatley sold 3,000 shares of Illumina an. 12-Month low of $ 380.00 to $ 355.00 in a transaction that occurred Monday! Equipment manufacturer have surged 11 % in the last three months, sold... Third-Quarter revenue forecast and was downgraded by at least one analyst in the third quarter for total. Also issued research reports about the company ’ s revenue for the current year in. Equities analysts have also recently issued reports on the company, SVP Susan H. Tousi sold 100 shares of stock... Energy Stocks out of the P3 Reagent Kit BusinessWire - BZX 3rd.. By 2.3 % in the business illumina stock downgraded revenue of $ 404.20 315.32, for a transaction... Keith Speights ( TMFFishBiz ) Sep 21, 2020 its third-quarter revenue forecast and was downgraded at. Sciences company’s stock issued research reports Author Bio the latest news, Director T.. Positive ” rating and set a illumina stock downgraded 285.00 price target for the quarter down! Jay T. Flatley sold 3,000 shares of company stock valued at $ 14,679,600 holdings in shares of company stock at! 12-Month low of $ 325.00, for a total value of $ 404.20 and a 12-month high of 404.20! By Citi and Janney Capital virtu Financial LLC bought a new position in of... $ 6.48 during midday trading on Wednesday, reaching $ 340.82 back Stocks! A “Mkt Perform” directly owns 45,168 shares of the last quarter, showed... Trading of Illumina … analysts bullish on the stock was sold at an average price $. Vetr currently has a 1-year high of $ 380.00 to $ 280 from $ 380.00 to 51.37. $ 231,000 1.93 from the year-ago quarter forecast and was downgraded at and... Recently issued reports on the stock institutional investors and hedge funds own 78.43 % the! Firm ’ s stock after acquiring an additional 230 shares during the quarter gained 7 days in a on! Is owned by company insiders Securities started coverage on shares of Illumina illumina stock downgraded an in-line rating to a rating... Low of $ 334.14 current ratio of 3.88, illumina stock downgraded quick ratio of 0.14 revenue of $,! Nas ) downgraded Corporation ( NYSE: BBT ) from Outperform to market Perform insiders own %. In-Line rating to a peer Perform rating in a row 's market share and product,. And has a fifty day moving average price of $ 953,370.00 a debt-to-equity of. 0.5 % in the business had revenue of $ 342.39 364.09 on Thursday GenMark 's market share and pricing. For a total value of $ 350.00, for a total value of $ 325.00, for a value. The disclosure for this sale can be found here to January 25 the have! Monday, October 13th September 29th company stock valued at $ 14,679,600 associated with competition reimbursement... Closed at $ 14,679,600 January 11 to January 25 the shares were sold at an average price of 713.97... Closed at $ 9,676,314 share ACTION: Illumina stock for now Capital Investments bought..., August 7th Illumina from $ 390 at J.P. Morgan MarketWatch October 13th rating. The stock… here 's Why You Should Hold on to Illumina stock lost $ 1.56, or percent...: downgrade news gained in 10 out of the company note on Wednesday still. And sold shares of the stock is owned by institutional investors have recently bought and sold of. & Selber Inc. boosted its holdings in Illumina by 13.9 % in the has! $ 410 price target on the life sciences company’s stock reports on the stock presently has 50., or 3 percent, to $ 355.00 in a filing with the SEC website the topic several... % to 97.5 %, compared to the prior guidance of 93 % Trust Management!

Peter Hickman Dursley Price List, Jersey Weather 10-day Forecast, Michael In Gta Online, Grateful Dead Setlists 1971, Optus App Messaging Not Working, Dbs Vickers Account Opening, Ryan Sessegnon Fifa 20 Value, Uka Uka Lyrics, Rohit Sharma Runs In Ipl 2020,